Adaptive Biotechnologies Plans to Split Its MRD and Immune Medicine Units
The company expects to decide the best path by year-end 2026.
/ 495 items
#XY Event-Driven Stocks↓
H.C. Wainwright Says CNTX Stock Drop Is 'Overdone' After CTIM-76 Ovarian Cancer Data
Context Therapeutics reported positive Phase 1 data for CTIM-76 in heavily pretreated platinum-resistant ovarian cancer, showing a 29% response rate and good safety, but the stock fell due to small trial size.
Analysts Reiterate Buy Ratings on Intellia as lonvo-z Shows Deeper Benefits in HAELO Trial
Intellia’s one-time gene therapy cut HAE attacks ~90%, boosting hopes for a lasting treatment; FDA review underway, launch possible in 2027.
Neumora Halts Navacaprant Development After Phase 3 Depression Trials Fail
Neumora stopped navacaprant after failed depression trials, cut 35% jobs, shares fell, but keeps advancing 3 other drugs.
Elicio Stock Falls After Phase 2 Pancreatic Cancer Trial Misses Primary Endpoint
Elicio stock plunged after Phase 2 failed main goal, but showed cancer benefit in selected patients.
Traws Pharma Puts Phase 2 Influenza Trial on Hold After UK Regulator Feedback
Traws Pharma shares fell after delaying its Phase 2 human influenza challenge study due to negative feedback from the UK’s MHRA. The company is now advancing backup flu antiviral candidates.